Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2014

View Archived Issues

Clinical phase I/II results of gene therapy for Becker muscular dystrophy

Phase II clinical results for a three-drug combination against HCV infection

GlaxoSmithKline plans phase II study of GSK-2269557 for acute exacerbation of COPD

New antagonists of S1P3 revert neurodegeneration and neuroinflammation

Nippon Kayaku launches infliximab biosimilar in Japan

Osteopontin RNA aptamer shows potential for the treatment of heart failure

LCZ-696 granted accelerated assessment by CHMP in Europe

Fullerene polyaminocaproic acid tested against HSV infection

Medicines for Malaria Venture collaborates with Cipla and Strides

UCB and Daiichi Sankyo partner to commercialize lacosamide in Japan

Aerocrine plans rights issue to fund commercialization of asthma diagnostic

Bukwang Pharmaceutical acquires Contera Pharma

Fingolimod fails to achieve endpoint in phase III trial in PPMS

Rinat Neuroscience discloses new anti-glucagon receptor antibodies

Incyte patents novel JAK-1 inhibitors

Roche patent reports new anti-HBV compounds

New mu opioid receptor antagonists designed at Dr August Wolff

Suzhou Vivotide Biotechnologies discloses novel VEGFR-1 inhibitors

Dynavax regains rights to DV-1179 under GSK collaboration

Mochida seeks approval in Japan for Lexapro in social anxiety disorder

Janssen files for manufacturing and distribution approval for ibrutinib in Japan

MSD and Kyorin sign Japanese comarketing agreement for desloratadine

EMA accepts for review Imbruvica submission for Waldenstrom's macroglobulinemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...